Compare Vaxcyte Inc. Common Stock (PCVX) vs State Street Corporation Common Stock (STT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vaxcyte Inc. Common Stock vs State Street Corporation Common Stock — how do they compare? Vaxcyte Inc. Common Stock trades at $67.37 (market cap $10.51B), while State Street Corporation Common Stock trades at $166.95 (market cap $47.83B). The key difference: State Street Corporation Common Stock is far larger — about 4.6× Vaxcyte Inc. Common Stock's market cap, and State Street Corporation Common Stock pays a 2.11% dividend while Vaxcyte Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Vaxcyte Inc. Common Stock for 0 Days and State Street Corporation Common Stock for 2 Days on average.
| PCVX | STT | |
|---|---|---|
Market Cap | $10.51B | $47.83B |
Volume | 2,644,694 | 2,907,463 |
Sector | Health | Financials |
52-Week High | $73.82 | $194.26 |
52-Week Low | $40.32 | $111.37 |
Typical Hold Time | 0 Days | 2 Days |
Enterprise Value | $9.14B | $74.34B |
Dividend Yield | — | 2.11% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
State Street (STT) trades at $173.99, down 0.54% with bearish technical signals despite strong Q3 2026 earnings beat. The stock faces headwinds from a revenue miss and ongoing investigation, though fundamentals show robust profitability with 22.95% net margin and consistent earnings growth. Analyst consensus remains positive with $183.55 price target, but technical indicators show selling pressure with support at $172.
Outlook is mixed with strong fundamentals supporting long-term value, but near-term risks from the securities investigation and bearish technicals create uncertainty. The 13% revenue growth and record AUM provide upside potential, though investors should monitor legal developments and expense trends that could impact sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vaxcyte Inc. Common Stock
Vaxcyte, Inc. is a clinical-stage vaccine company that engineers protein-based vaccines to prevent bacterial diseases such as invasive pneumococcal disease, using its proprietary cell-free protein synthesis platform to develop candidates including the pneumococcal conjugate vaccines VAX-31 and VAX-24.
Read more on PCVX →About State Street Corporation Common Stock
State Street provides investment servicing, custody, and asset management services to institutional investors. Its asset management business includes the SPDR ETF range.
Read more on STT →
